Shining a light on intestinal traffic.

Typeset version

 

TY  - JOUR
  - Murphy CT, Nally K, Shanahan F, Melgar S
  - 2012
  - January
  - Clinical ; developmental immunology
  - Shining a light on intestinal traffic.
  - Validated
  - ()
  - 2012
  - Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is associated with enhanced leukocyte infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte trafficking is a major target for IBD therapy. Past and emerging techniques to study leukocyte trafficking both in vitro and in vivo have expanded our knowledge of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there is an abundance of preclinical data demonstrating efficacy of leukocyte trafficking inhibitors, many have yet to be confirmed in clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.
  - 10.1155/2012/808157
  - Science Foundation Ireland
DA  - 2012/01
ER  - 
@article{V139284394,
   = {Murphy CT,  Nally K and  Shanahan F,  Melgar S },
   = {2012},
   = {January},
   = {Clinical ; developmental immunology},
   = {Shining a light on intestinal traffic.},
   = {Validated},
   = {()},
   = {2012},
   = {{Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is associated with enhanced leukocyte infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte trafficking is a major target for IBD therapy. Past and emerging techniques to study leukocyte trafficking both in vitro and in vivo have expanded our knowledge of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there is an abundance of preclinical data demonstrating efficacy of leukocyte trafficking inhibitors, many have yet to be confirmed in clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.}},
   = {10.1155/2012/808157},
   = {Science Foundation Ireland},
  source = {IRIS}
}
AUTHORSMurphy CT, Nally K, Shanahan F, Melgar S
YEAR2012
MONTHJanuary
JOURNAL_CODEClinical ; developmental immunology
TITLEShining a light on intestinal traffic.
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORD
VOLUME2012
ISSUE
START_PAGE
END_PAGE
ABSTRACTInflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is associated with enhanced leukocyte infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte trafficking is a major target for IBD therapy. Past and emerging techniques to study leukocyte trafficking both in vitro and in vivo have expanded our knowledge of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there is an abundance of preclinical data demonstrating efficacy of leukocyte trafficking inhibitors, many have yet to be confirmed in clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.
PUBLISHER_LOCATION
ISBN_ISSN
EDITION
URL
DOI_LINK10.1155/2012/808157
FUNDING_BODYScience Foundation Ireland
GRANT_DETAILS